PROTECTING YOUR RIGHT TO MEDICINES AND MEDICAL DEVICES
Wednesday, 01 April 2020

Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. The concept of pharmacovigilance is borne out of the recognition that no medicine is completely risk-free.

The specific aims of pharmacovigilance are to:

  • improve patient care and safety in relation to the use of medicines and all medical and paramedical interventions,
  • improve public health and safety in relation to the use of medicines,
  • contribute to the assessment of benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and more effective (including cost-effective) use, and
  • promote understanding, education and clinical training in pharmacovigilance and its effective communication to the public.

Source: The Importance of Pharmacovigilance, WHO 2002

MCAZ houses the National Pharmacovigilance Centre which participates in the WHO Programme for International Drug Monitoring

The Authority wishes to notify stakeholders of the addition of several new methods of submitting Adverse Drug Reaction (ADR) reports, Serious Adverse Events (SAE) reports for clinical trials, Adverse Events Following Immunisation (AEFI) reports and SAE reports from pharmaceutical industry I E2B format.

The new methods include use of the Android Mobile App, Apple iOs Mobile App, Windows Desktop App, MacOs Desktop App, Linux Desktop App, as well as the Browser-Based Web App. These can be accessed from the respective links on this page.

 

Latest News

Draft SADC Variations Guidelines

20 March 2020

Draft SADC Variations Guidelines are now available  Click the following links to download the guidelines and the comments sheet Draft SADC Variations Guidelines Draft SADC Variations Guidelines Comments Sheet

Medicines Information Bulletin - 2019

20 December 2019
Medicines Information Bulletin - 2019

Inside this issue: E-Reporting Tools Safety Notifications for Fluoroquinolones and Quinolones Antibiotics Notification of a potential risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) in patients treated...

Code of Ethics

22 August 2019
Code of Ethics

  In pursuit of promoting high ethical standards, the Authority has formulated a Code of Ethics for its employees and members of the Authority .The Authority believes that high ethical...

SADC Guideline on Product Information and Labeling

10 July 2019
SADC Guideline on Product Information and Labeling

  Southern African Development Community (SADC), as a region has harmonized medicines registration guidelines in the common technical document (CTD) format that were approved in January 2015. Nevertheless, the harmonization...

Draft Guidelines For Comments Only: Guideline for Submitting Application for Variations to Registered Medicines

17 May 2019
Draft Guidelines For Comments Only: Guideline for Submitting Application for Variations to Registered Medicines

In line with the WHO guidelines on variations and other SRA guidelines, the EVR Division is updating the MCAZ Guidelines for submitting applications for Variations to Registered Medicines. The update...

Careers @ MCAZ

30 October 2018

The Medicines Control Authority of Zimbabwe (MCAZ) is inviting suitably qualified, honest, self-motivated applicants for the following post: REGULATORY OFFICER x1 POST - LICENSING AND ENFORCEMENT DIVISION Reporting to the...

Fellowship in regulatory science for African Medicine Reviewers/Assessors

26 October 2018
Fellowship in regulatory science for African Medicine Reviewers/Assessors

  Background   The Medicines Control Authority of Zimbabwe (MCAZ) Regional Centre of Regulatory Excellence (ReCORE) in partnership with the European and Developing Countries Clinical Trials Partnership (EDCTP) is offering...

Quality Policy Statement

06 July 2018
Quality Policy Statement

The Quality Policy of the Medicines Control Authority of Zimbabwe (MCAZ) is to ensure the provision of accurate and timeous services, continuously meet requirements of our customers and guarantee patient...

MCAZ Newsletter

10 May 2018
MCAZ Newsletter

In this issue: MCAZ turns 20 years Basics of reporting Side Effects of medicines Electronic Adverse Drug Reaction Reporting   For more information Please click here to download the Newsletter...

Medicines Information Bulletin - 2018

02 February 2018
Medicines Information Bulletin - 2018

Increased Reporting from the Targeted Spontaneous Reporting (TSR) Programme Click here to download the 2018 Drug Information Bulletin